Novel HER3 Agents for EGFR-Mutated NSCLC
New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Released: December 17, 2024

Expiration: December 16, 2025

Karen Reckamp
Karen Reckamp, MD, MS
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed